Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Trial of Bendamustine Plus Alemtuzumab for the Treatment of Fludarabine Refractory Chronic Lymphocytic Leukemia

NCT00947388 is registered in ClinicalTrials.gov with Case Comprehensive Cancer Center as lead sponsor.

NCT NCT00947388
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00947388 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Trial of Bendamustine Plus Alemtuzumab for the Treatment of Fludarabine Refractory Chronic Lymphocytic Leukemia
Lead sponsor
Case Comprehensive Cancer Center
Phase
Phase 1
Overall status
Terminated
Start date
November 30, 2008
Completion date
March 31, 2013
Enrollment
9 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

recurrent small lymphocytic lymphoma, refractory chronic lymphocytic leukemia, stage iii chronic lymphocytic leukemia, stage iii small lymphocytic lymphoma, stage iv chronic lymphocytic leukemia, stage iv small lymphocytic lymphoma